Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454618 | 1.00 | CTSK (0.55) | CTSKCTSSPPARAPPARGITGB3 | |
| SCHEMBL16934137 | 0.89 | CTSK (0.52) | CTSKCTSSS1PR2S1PR1 | |
| SCHEMBL5447774 | 0.89 | CTSK (0.52) | CTSKCTSSS1PR2S1PR1 | |
| SCHEMBL16934135 | 0.89 | CTSK (0.52) | CTSKCTSSS1PR2S1PR1 | |
| SCHEMBL16945658 | 0.89 | CTSK (0.52) | CTSKCTSSS1PR2S1PR1 | |
| SCHEMBL10151227 | 0.87 | CTSK (0.58) | CTSKCTSSPPARAPPARGITGB3 | |
| SCHEMBL12305804 | 0.87 | CTSK (0.58) | CTSKCTSSPPARAPPARGITGB3 | |
| SCHEMBL16945662 | 0.87 | CTSK (0.50) | CTSKCTSSS1PR2S1PR1 | |
| SCHEMBL23177045 | 0.85 | CTSK (0.60) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL24814896 | 0.85 | CTSK (0.60) | CTSKCTSSPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309721-B2 | Immunosuppressants for treating diseases and conditions of bone marrow, organ and tissue transplant rejection; chemotherapeutic drug for cancers; antiinflammatory agents for rheumatoid arthritis; activate the production of lymphocyte; 2-Amino-4-(4-(octylphenyl))butanol, O-phosphate | MERCK + CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | DOHERTY GEORGE A | 2007-09-27 | — | — | US | disclosed |
| US-20060089334-A1 | Aminoalkylphosphonates and related compounds as edg receptor agonists | MERCK & CO., INC. | 2006-04-27 | — | — | US | disclosed |
| EP-1482896-A4 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050107345-A1 | Aminoalkylphosphonates and related compounds as edg receptor agonists | DOHERTY GEORGE A (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1482895-A4 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1482896-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1482895-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074008-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003073986-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089334-A1 | Aminoalkylphosphonates and related compounds as edg receptor agonists | ADGRF1, EDNRA, ADGRE5 | CTSK 2584/4885CTSS 2677/4885PPARA 314/4885 |
| US-20050107345-A1 | Aminoalkylphosphonates and related compounds as edg receptor agonists | EDNRA, ADGRE5, ADGRF1 | CTSK 2625/4885CTSS 2771/4885PPARA 319/4885 |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | ADGRE5, EDNRA, ADGRF1 | CTSK 2374/4885CTSS 2395/4885PPARA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.